
Andrew W. Johns
Examiner (ID: 13016, Phone: (571)272-7391 , Office: P/2665 )
| Most Active Art Unit | 2665 |
| Art Unit(s) | 2624, 2606, 2662, 2714, 2621, 2665, 2616, 2721, 2899 |
| Total Applications | 2451 |
| Issued Applications | 2078 |
| Pending Applications | 135 |
| Abandoned Applications | 240 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18252874
[patent_doc_number] => 20230079913
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-16
[patent_title] => GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/751136
[patent_app_country] => US
[patent_app_date] => 2022-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 163683
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17751136
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/751136 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | May 22, 2022 | Abandoned |
Array
(
[id] => 18268132
[patent_doc_number] => 20230089374
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-23
[patent_title] => GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/751144
[patent_app_country] => US
[patent_app_date] => 2022-05-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 163679
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17751144
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/751144 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | May 22, 2022 | Abandoned |
Array
(
[id] => 18117511
[patent_doc_number] => 11548892
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2023-01-10
[patent_title] => Transglutaminase 2 (TG2) inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/749335
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 123910
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 5
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749335
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/749335 | Transglutaminase 2 (TG2) inhibitors | May 19, 2022 | Issued |
Array
(
[id] => 19571800
[patent_doc_number] => 20240376092
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => MODULATORS OF PrPC AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/562896
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27303
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562896
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562896 | MODULATORS OF PrPC AND USES THEREOF | May 19, 2022 | Pending |
Array
(
[id] => 19333669
[patent_doc_number] => 20240248099
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-25
[patent_title] => BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION
[patent_app_type] => utility
[patent_app_number] => 18/562768
[patent_app_country] => US
[patent_app_date] => 2022-05-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31660
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -85
[patent_words_short_claim] => 81
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18562768
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/562768 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | May 19, 2022 | Pending |
Array
(
[id] => 18825263
[patent_doc_number] => 11840533
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-12
[patent_title] => Pyridinone-based epigenetic modifiers and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/663499
[patent_app_country] => US
[patent_app_date] => 2022-05-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 11
[patent_no_of_words] => 27751
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 679
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17663499
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/663499 | Pyridinone-based epigenetic modifiers and uses thereof | May 15, 2022 | Issued |
Array
(
[id] => 19165771
[patent_doc_number] => 11981657
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Substituted benzimidazoles, their preparation and their use as pharmaceuticals
[patent_app_type] => utility
[patent_app_number] => 17/743792
[patent_app_country] => US
[patent_app_date] => 2022-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48062
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 311
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17743792
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/743792 | Substituted benzimidazoles, their preparation and their use as pharmaceuticals | May 12, 2022 | Issued |
Array
(
[id] => 17830022
[patent_doc_number] => 20220267326
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-08-25
[patent_title] => CRYSTALLINE FORM OF VALBENAZINE DITOSYLATE, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/738534
[patent_app_country] => US
[patent_app_date] => 2022-05-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7026
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 36
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17738534
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/738534 | CRYSTALLINE FORM OF VALBENAZINE DITOSYLATE, PROCESSES FOR PREPARATION THEREOF AND USE THEREOF | May 5, 2022 | Abandoned |
Array
(
[id] => 18948108
[patent_doc_number] => 11891389
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-06
[patent_title] => PGDH inhibitors and methods of making and using
[patent_app_type] => utility
[patent_app_number] => 17/725220
[patent_app_country] => US
[patent_app_date] => 2022-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 68086
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 291
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17725220
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/725220 | PGDH inhibitors and methods of making and using | Apr 19, 2022 | Issued |
Array
(
[id] => 20372420
[patent_doc_number] => 12479842
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-25
[patent_title] => Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease
[patent_app_type] => utility
[patent_app_number] => 18/287610
[patent_app_country] => US
[patent_app_date] => 2022-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 122915
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18287610
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/287610 | Pyrido[3,2-d]pyrimidine compounds uses thereof for treating a proliferative disease | Apr 18, 2022 | Issued |
Array
(
[id] => 19246744
[patent_doc_number] => 20240197728
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY
[patent_app_type] => utility
[patent_app_number] => 18/555425
[patent_app_country] => US
[patent_app_date] => 2022-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13157
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18555425
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/555425 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING REFRACTORY EPILEPSY | Apr 12, 2022 | Pending |
Array
(
[id] => 19299936
[patent_doc_number] => 20240228505
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-11
[patent_title] => BICYCLIC PYRIDINE DERIVATIVE
[patent_app_type] => utility
[patent_app_number] => 18/554525
[patent_app_country] => US
[patent_app_date] => 2022-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -59
[patent_words_short_claim] => 817
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18554525
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/554525 | Bicyclic pyridine derivative | Apr 7, 2022 | Issued |
Array
(
[id] => 19248697
[patent_doc_number] => 20240199684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-20
[patent_title] => PROCESS FOR THE PREPARATION OF DROSPIRENONE AS A FINE POWDER THROUGH A DOUBLE CHANGE OF CRYSTALLINE FORM
[patent_app_type] => utility
[patent_app_number] => 18/553923
[patent_app_country] => US
[patent_app_date] => 2022-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3719
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553923
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/553923 | PROCESS FOR THE PREPARATION OF DROSPIRENONE AS A FINE POWDER THROUGH A DOUBLE CHANGE OF CRYSTALLINE FORM | Apr 7, 2022 | Pending |
Array
(
[id] => 18801311
[patent_doc_number] => 11834462
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-05
[patent_title] => Somatostatin modulators and uses thereof
[patent_app_type] => utility
[patent_app_number] => 17/714825
[patent_app_country] => US
[patent_app_date] => 2022-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23086
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714825
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/714825 | Somatostatin modulators and uses thereof | Apr 5, 2022 | Issued |
Array
(
[id] => 19464089
[patent_doc_number] => 20240317758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => NEK7 INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 18/553828
[patent_app_country] => US
[patent_app_date] => 2022-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37227
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553828
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/553828 | NEK7 INHIBITORS | Apr 4, 2022 | Pending |
Array
(
[id] => 19265230
[patent_doc_number] => 20240208929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-06-27
[patent_title] => HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/553829
[patent_app_country] => US
[patent_app_date] => 2022-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20302
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -79
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18553829
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/553829 | HYDROXYPYRIDINE HSD17B13 INHIBITORS AND USES THEREOF | Apr 3, 2022 | Pending |
Array
(
[id] => 19210680
[patent_doc_number] => 11999728
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-04
[patent_title] => Estrogen receptor modulators
[patent_app_type] => utility
[patent_app_number] => 17/657841
[patent_app_country] => US
[patent_app_date] => 2022-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 2
[patent_no_of_words] => 37093
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17657841
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/657841 | Estrogen receptor modulators | Apr 3, 2022 | Issued |
Array
(
[id] => 18801300
[patent_doc_number] => 11834451
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-05
[patent_title] => Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection
[patent_app_type] => utility
[patent_app_number] => 17/705984
[patent_app_country] => US
[patent_app_date] => 2022-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 20245
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17705984
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/705984 | Compositions and methods for inhibiting virus protein 2C activity and for preventing and treating non-polio enterovirus infection | Mar 27, 2022 | Issued |
Array
(
[id] => 18762880
[patent_doc_number] => 11813259
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-14
[patent_title] => Benzamide compounds
[patent_app_type] => utility
[patent_app_number] => 17/656726
[patent_app_country] => US
[patent_app_date] => 2022-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 7
[patent_no_of_words] => 43027
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 13
[patent_words_short_claim] => 48
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17656726
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/656726 | Benzamide compounds | Mar 27, 2022 | Issued |
Array
(
[id] => 17896964
[patent_doc_number] => 20220306626
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-29
[patent_title] => CRYSTALLINE FORM OF A DIHYDROCHLORIDE SALT OF A JAK INHIBITOR COMPOUND
[patent_app_type] => utility
[patent_app_number] => 17/704502
[patent_app_country] => US
[patent_app_date] => 2022-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11763
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17704502
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/704502 | CRYSTALLINE FORM OF A DIHYDROCHLORIDE SALT OF A JAK INHIBITOR COMPOUND | Mar 24, 2022 | Abandoned |